COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Muscle Mass

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02519751
Recruitment Status : Completed
First Posted : August 11, 2015
Last Update Posted : August 11, 2015
Information provided by (Responsible Party):

Brief Summary:
Creatine (methyl-d3) dilution (D3-creatine) is a novel technique for the estimation of muscle mass. The method uses a dose of deuterium-labelled creatine to determine total skeletal muscle mass via estimation of total body creatine pool size.The aim of this study is to compare estimates of total body skeletal muscle mass by D3-creatine dilution method and whole body Magnetic Resonance Imaging (MRI) in an athletic population.

Condition or disease Intervention/treatment Phase
Sports Nutritional Sciences Dietary Supplement: D3 Creatine Dietary Supplement: Creatine Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Total Body Skeletal Muscle Mass Estimation by Creatine (Methyl-d3) Dilution in Athletes
Study Start Date : October 2014
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: D3 Creatine followed by creatine supplementation
Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 mass/day, increasing on weekly basis. Final dose of 0.05 mass/day is then maintained throughout the study.
Dietary Supplement: D3 Creatine
One dose of D3 Creatine (60mg capsule) given orally on Day 1

Dietary Supplement: Creatine
Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 mass/day, increasing on a weekly basis. Final dose of 0.05 mass/day is then maintained throughout the study.

Primary Outcome Measures :
  1. Correlation between muscle mass obtained by MRI method and D3-Creatine method [ Time Frame: Upto 3 months ]
    MRI scan of the participants will be done at Day 1 and end of study (i.e.Day 90).D3-Creatine capsule will be given orally at Day 1 and urine samples collected at 0-4h and 4-24h every day from Day 1 to Day 4.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Trained and competing elite canoe athletes will be recruited, who represent Great Britain Canoeing

Exclusion Criteria:

  • Pregnant and lactating women
  • Intolerance or hypersensitivity to Creatine supplementation
  • Athletes with disabilities which affect their total body muscle mass
  • If creatine was taken in a supplemented form, rather than dietary intake, more regularly than once a week within 6-weeks of assessment commencing
  • Contraindication to an MRI scan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02519751

Layout table for location information
United Kingdom
GSK Investigational Site
Brentford, United Kingdom, TW8 9 DA
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT02519751    
Other Study ID Numbers: 202600
First Posted: August 11, 2015    Key Record Dates
Last Update Posted: August 11, 2015
Last Verified: August 2015